Options activity tied to Akba stock forecast has ticked up, with call contracts showing open interest at strike prices above $1. The analysts covering Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. Displays a symbol's price movements over previous years to identify recurring trends. Sector rotation trends show increasing interest in biotech plays, benefiting Akba stock forecast. The company’s drug development milestones are perceived as value drivers, especially in an environment of heightened healthcare focus.